Abiomed, Inc.
Abiomed, Inc., a leading player in the cardiovascular medical device industry, is headquartered in the United States. Founded in 1981, the company has made significant strides in developing innovative heart pump technologies, particularly in the areas of heart recovery and circulatory support. With a focus on products such as the Impella heart pump, Abiomed has distinguished itself through its commitment to improving patient outcomes and advancing heart care. The company operates primarily in North America and Europe, positioning itself as a pioneer in minimally invasive heart pump solutions. Notable achievements include the FDA approval of its devices, which have transformed the treatment landscape for patients with severe coronary artery disease. Abiomed continues to lead the market with its cutting-edge technology and dedication to enhancing the quality of life for patients worldwide.
DitchCarbon Score
How does Abiomed, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Abiomed, Inc.'s score of 78 is higher than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Abiomed, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. As a current subsidiary of Johnson & Johnson, any climate commitments or emissions data would be inherited from its parent company. Abiomed is aligned with several climate initiatives through Johnson & Johnson, including the Science Based Targets initiative (SBTi), CDP, and RE100, all of which are cascaded from Johnson & Johnson at a corporate family level. However, there are no specific reduction targets or achievements reported for Abiomed itself. The absence of direct emissions data suggests that Abiomed is still in the process of establishing its own climate commitments, while leveraging the sustainability framework and initiatives of Johnson & Johnson. This relationship indicates a commitment to broader corporate sustainability goals, although specific metrics for Abiomed's emissions and reduction targets remain unspecified.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 1990 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 308,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 751,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 00,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Abiomed, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
